Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab

Thrombosis and Haemostasis

Volumn 113, Issue 4, 2015, Pages 728-740

  Honickel, Markus ^a   Treutler, Stefanie ^a   van Ryn, Joanne ^b   Tillmann, Sabine ^a   Rossaint, Rolf ^a   Grottke, Oliver ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Dabigatran; Idarucizumab; Prothrombin complex concentrate; Thrombin generation; Trauma

Indexed keywords

BLOOD CLOTTING FACTOR 9 CONCENTRATE; DABIGATRAN; DABIGATRAN ETEXILATE; FIBRINOGEN CONCENTRATE; HEMOGLOBIN; HEMOSTATIC AGENT; IDARUCIZUMAB; PROTHROMBIN; PROTHROMBIN COMPLEX; THROMBIN; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR; COAGULATING AGENT; FIBRINOGEN; MONOCLONAL ANTIBODY; PROTHROMBIN COMPLEX CONCENTRATES;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD ANALYSIS; BLOOD CLOT FORMATION TIME; BLOOD CLOT STRENGTH; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HEMATOLOGICAL PROCEDURE; MULTIPLE TRAUMA; NONHUMAN; PIG; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOELASTOMETRY; ANIMAL; BLOOD; BLOOD CLOTTING TEST; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIFIBRINOLYTIC AGENTS; ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; COAGULANTS; DABIGATRAN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOGEN; INFUSIONS, INTRAVENOUS; MALE; MULTIPLE TRAUMA; SWINE; THROMBIN; TIME FACTORS; TRANEXAMIC ACID;

EID: 84931264466     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-08-0712     Document Type: Article

References (44)

1. Pradaxa summary of product characteristics. Available from: http://www. medi cines. org. uk/emc/medicine/20760#INDICATIONS. Accessed August 2014.
2. van Ryn J, Goss A, Hauel N et al. The discovery of dabigatran etexilate. Front Pharmacol 2013; 4: 12.
3. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
4. Spahn DR, Bouillon B, Cerny V et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013; 17: R76.
5. Liesenfeld KH, Staab A, Hartter S et al. Pharmacometric characterization of dabigatran hemodialysis. Clin Pharmacokinet 2013; 52: 453-462.
6. Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
7. Dickneite G, Pragst I. Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model. Br J Anaesth 2009; 102: 345-354.
8. Grottke O, Braunschweig T, Spronk HM et al. Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood 2011; 118: 1943-1951.
9. Honickel M, Rieg A, Rossaint R et al. Prothrombin complex concentrate reduces blood loss and enhances thrombin generation in a pig model with blunt liver injury under severe hypothermia. Thromb Haemost 2011; 106: 724-733.
10. Grottke O, Rossaint R, Henskens Y et al. Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model. PLoS One 2013; 8: e64100.
11. Sarode R, Milling TJ, Jr., Refaai MA et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128: 1234-1243.
12. Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 2014; 111: 189-198.
13. Siegal DM, Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis 2013; 35: 391-398.
14. Grottke O, van Ryn J, Spronk HM et al. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care 2014; 18: R27.
15. Herzog E, Kaspereit FJ, Krege W et al. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model. Thromb Res 2014; 134: 729-736.
16. Pragst I, Zeitler SH, Doerr B et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012; 10: 1841-1848.
17. CRASH-2 collaborators, Roberts I, Shakur H et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377: 1096-1101.
18. Davenport R, Brohi K. Fibrinogen depletion in trauma: early, easy to estimate and central to trauma-induced coagulopathy. Crit Care 2013; 17: 190.
19. Rourke C, Curry N, Khan S et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost 2012; 10: 1342-1351.
20. Schlimp CJ, Voelckel W, Inaba K et al. Impact of fibrinogen concentrate alone or with prothrombin complex concentrate (+/-fresh frozen plasma) on plasma fibrinogen level and fibrin-based clot strength (FIBTEM) in major trauma: a retrospective study. Scand J Trauma Resusc Emerg Med 2013; 21: 74.
21. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals. 7th edition. Washington DC: National Academy Press, 1996.
22. Baker TA, Romero J, Bach HH 4th et al. Systemic release of cytokines and heat shock proteins in porcine models of polytrauma and hemorrhage. Crit Care Med 2012; 40: 876-885.
23. Grottke O, Braunschweig T, Philippen B et al. A new model for blunt liver injuries in the swine. Eur Surg Res 2010; 44: 65-73.
24. Spronk HM, Dielis AW, De Smedt E et al. Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory. Thromb Haemost 2008; 100: 362-364.
25. Honickel M, Van Ryn J, Spronk HM et al. Prothrombin complex concentrate restores haemostasis in a dabigatran anticoagulated polytrauma pig model. Crit Care 2014; 18 (Suppl 1): P115.
26. van Ryn J, Schurer J, Kink-Eiband M et al. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology 2014; 120: 1429-1440.
27. Lambourne MD, Eltringham-Smith LJ, Gataiance S et al. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost 2012; 10: 1830-1840.
28. Zhou W, Schwarting S, Illanes S et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
29. Herrmann R, Thom J, Wood A et al. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 2014; 111: 989-995.
30. Marlu R, Hodaj E, Paris A et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
31. Harinstein LM, Morgan JW, Russo N. Treatment of dabigatran-associated bleeding: case report and review of the literature. J Pharm Pract 2013; 26: 264-269.
32. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
33. Schochl H, Voelckel W, Maegele M et al. Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients. Crit Care 2014; 18: R147.
34. Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89: 228-232.
35. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med 2011; 365: 2039-2040.
36. Glund S, Stangier J, Schmohl M et al. A Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Healthy Male Volunteers. Circulation 2013; 128: A17765.
37. Grottke O. Coagulation management. Curr Opin Crit Care 2012; 18: 641-646.
38. Kind SL, Spahn-Nett GH, Emmert MY et al. Is dilutional coagulopathy induced by different colloids reversible by replacement of fibrinogen and factor XIII concentrates? Anesth Analg 2013; 117: 1063-1071.
39. Zentai C, Braunschweig T, Schnabel J et al. Fibrinogen Concentrate Does Not Suppress Endogenous Fibrinogen Synthesis in a 24-hour Porcine Trauma Model. Anesthesiology 2014; 121: 753-764.
40. Wagner CL, Mascelli MA, Neblock DS et al. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88: 907-914.
41. Fries D, Innerhofer P, Reif C et al. The effect of fibrinogen substitution on reversal of dilutional coagulopathy: an in vitro model. Anesth Analg 2006; 102: 347-351.
42. Grottke O, Braunschweig T, Henzler D et al. Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury. Crit Care 2010; 14: R62.
43. Connors NJ, Gill J, Nakanishi A et al. Porcine blood and surrogate markers do not prove benefit of aDabi-Fab. Crit Care 2014; 18: 435.
44. Tanaka KA, Bolliger D. On the reversal of new oral anti-coagulants: can we simply extrapolate data from the animal models to humans? Br J Anaesth 2013; 110: 329-332.